BUREAU-VERITAS
22.2.2024 09:45:27 CET | Business Wire | Press release
Regulatory News:
2023 Key Figures1
- Revenue of EUR 5,867.8 million for the full year 2023, up 8.5% organically and up 3.8% on a reported basis (including a positive 0.6% scope effect and a negative 5.3% currency fluctuations)
- In the fourth quarter, organic revenue growth achieved 9.4%
- Adjusted operating profit of EUR 930.2 million, up 3.1% versus EUR 902.1 million in 2022, representing an adjusted operating margin of 15.9%, down c.10 basis points on a reported basis, and up 20 basis points organically at 16.2% (of which +c.50bps in H2 2023)
- Operating profit of EUR 824.4 million, up 3.1% versus EUR 799.3 million in 2022
- Attributable net profit of EUR 503.7 million, up 7.9% versus EUR 466.7 million in 2022
- Adjusted net profit of EUR 574.7 million (adjusted EPS of EUR 1.27 per share), up 7.6% versus EUR 533.9 million in 2022 and up 17.6% at constant currency
- Free cash flow of EUR 659.1 million (11% of Group revenue), up 0.3% year-on-year and 5.5% at constant currency, led by disciplined capex policy and working capital management
- Adjusted net debt/EBITDA ratio2 reduced to 0.92x as of December 31, 2023, versus 0.97x last year
- Proposed dividend of EUR 0.83 per share3, up 7.8% year-on-year, payable in cash
2023 Highlights
- Appointment of a new CEO and strengthening of the Executive Committee to support future growth ambitions
- 2023 financial targets exceeded on all metrics
- Over 80% of the portfolio delivered at least mid-to-high single digit or double-digit organic revenue growth driven by good momentum in the sales pipeline
- Strong growth in every region (Americas, Middle East, Europe, Africa and Asia-Pacific), substantially outperforming many underlying markets
- Strong momentum maintained for Sustainability and energy transition solutions across the entire portfolio
- Acquisition of two bolt-on companies further diversifying Consumer Products Services adding annualized revenue of c. EUR 28 million. This includes ANCE, the leading player in Mexico for Electrical and Electronics products (c. EUR 21 million of revenue), announced today
- Good progress towards the achievement of the 2025 CSR ambitions; commitment recognized by several non-financial rating agencies, including a first ranking in the 2023 S&P Global rating (DJSI); mid-term GHG emissions targets approved by the Science Based Targets initiative (SBTi)
2024 Outlook
Leveraging a healthy and growing sales pipeline, high customer demand for ‘new economy services’ and strong underlying market growth, Bureau Veritas expects to deliver for the full year 2024:
- Mid-to-high single-digit organic revenue growth;
- Improvement in adjusted operating margin at constant exchange rates;
- Strong cash flow, with a cash conversion above 90%.
The Group expects H2 organic revenue growth above H1 (with stronger comparables in H1).
Hinda Gharbi, Chief Executive Officer, commented:
“We delivered very strong results in 2023, reflecting our robust business fundamentals, our consistent execution and our customer centricity around the globe. We achieved organic growth of 8.5%, a healthy organic margin of 16.2%, and record earnings per share of EUR 1.27, up over 17% at constant exchange rates.
I would like to warmly thank all our colleagues around the world for their dedication and hard work to deliver this outstanding performance.
I also want to thank our shareholders for their continued support. As a result of our robust cash flow generation and financials, the Board is recommending a dividend increase of 8% compared to last year.
I am convinced that we can take Bureau Veritas to higher levels of performance and achievement. Our portfolio of leading global business lines, strong execution track record and exposure to positive secular trends are key contributors to our current performance and a great foundation for future outperformance.
Specifically, we expect powerful demand for services supporting transition to sustainable development models, evolving buildings integrity needs, growing infrastructure investment and increased spending in low-carbon energy development. Our current pipeline of opportunities in these business areas is a testament to this durable growth dynamic. I look forward to updating the market with our vision and new strategy at our Capital Markets Day on March 20th.
For 2024, we expect Bureau Veritas to deliver another strong year of organic revenue growth, margin expansion4 and strong cash conversion.”
Click here to download the complete Press Release.
About Bureau Veritas
Bureau Veritas is a world leader in laboratory testing, inspection and certification services. Created in 1828, the Group has circa 82,000 employees located in nearly 1,600 offices and laboratories around the globe. Bureau Veritas helps its 400,000 clients improve their performance by offering services and innovative solutions in order to ensure that their assets, products, infrastructure and processes meet standards and regulations in terms of quality, health and safety, environmental protection and social responsibility.
Bureau Veritas is listed on Euronext Paris and belongs to the CAC 40 ESG, CAC Next 20, CAC 40 SBT 1.5, and SBF 120 indices. Compartment A, ISIN code FR 0006174348, stock symbol: BVI.
For more information, visit www.bureauveritas.com, and follow us on Twitter (@bureauveritas) and LinkedIn.
1 Alternative performance indicators are presented, defined and reconciled with IFRS in appendices 6 and 8 of this press release.
2 Ratio of adjusted net financial debt divided by consolidated EBITDA (earnings before interest, tax, depreciation, amortization and provisions), adjusted for any entities acquired over the last 12 months.
3 Proposed dividend, subject to Shareholders’ Meeting approval on June 20, 2024.
4 At constant currency
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240221228025/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release
Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur
Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
